Key Points
Nextoxin maintains its dedication to safety and reliability. The molecular weight of the protein subunits comprising the botlinum toxin type A complex was consistent with Nextoxin's specifications and was verified using SDS-PAGE analysis.
The findings highlight Nextoxin's efficacy in addressing moderate to severe glabellar lines. In a study involving 278 participants with these specific lines, both Nextoxin and B***x, the leading botulinum toxin product in the market (generic name: onabotulinumtoxinA / origin: USA), demonstrated comparable rates of improvement in glabellar lines and patient satisfaction levels. This observation was consistent
across evaluations conducted at 4, 8, 12, and 16 weeks post-injection. Importantly, statistical analysis revealed no significant difference in improvement rates between the two groups, affirming that Nextoxin is comparable to the much costlier industry leading toxin brand.
Throughout a 36-month long-term stability assessment, Nextoxin demonstrated no alterations in its physical or chemical attributes, consistently meeting safety and effectiveness benchmarks. Furthermore, potency assessments
yielded consistent results over the duration of testing.
Ensuring stability and maintaining high potency are paramount to achieving predictable outcomes and minimizing the risk of under or over-treatment. Through stringent control measures implemented during the manufacturing process, Nextoxin assures optimal efficacy and safety. This commitment empowers both patients and healthcare providers, instilling confidence in the product's reliability and performance.